《論文_澤菲聯(lián)合蓋諾治療不耐受順鉑晚期非小細(xì)胞肺癌臨床觀察(定稿)》

《《論文_澤菲聯(lián)合蓋諾治療不耐受順鉑晚期非小細(xì)胞肺癌臨床觀察(定稿)》》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。

1、澤菲聯(lián)合蓋諾治療不耐受順鉗晚期非小細(xì)胞肺癌臨床觀察福建醫(yī)科大學(xué)教學(xué)醫(yī)院福州肺科醫(yī)院腫瘤內(nèi)科陳群李育宏石琴謝強(qiáng)陳雨燕王成輝王琳摘要目的觀察并評(píng)價(jià)澤菲聯(lián)合蓋諾治療不能耐受順釦的晚期非小細(xì)胞肺癌的療效和毒性。方法108例III和IV期非小細(xì)胞肺癌既往均未曾放療或化療，按ECOG計(jì)分W2,生存期超過(guò)三個(gè)月。WBC計(jì)數(shù)〉4.0X109/L,肝、腎功能生化指標(biāo)正常，未有活動(dòng)性感染征象。36例以澤菲聯(lián)合蓋諾(GN)為一線方案，另外36例以吉西他濱加順鉗(GP),36例以長(zhǎng)春瑞濱加順鉗(NP)為一線方案作對(duì)照纟(I。結(jié)果GP組、NP組和GN纟

2、flRR%分另I」為44.4%、41.7%和36」％,三組療效比較,宀0.421,P=1.731,(P值>0.05)無(wú)統(tǒng)計(jì)學(xué)差異性。三組的癥狀緩解率、全身體力狀況改善、TTP、一年生存率等亦無(wú)顯著性差異。GN組與另兩組在III?IV度血液學(xué)毒性方面比較無(wú)統(tǒng)計(jì)學(xué)差界(P>0.05)；GN組非血液學(xué)毒性比較少，生活質(zhì)量的影響較少，均有統(tǒng)計(jì)學(xué)差異性。結(jié)論GN方案療效較好，毒性較低，具有良好耐受的方案，尤其適合于不能耐受順鈉的晚期NSCLC患者。關(guān)鍵詞非小細(xì)胞肺癌；化學(xué)療法；吉西他濱；長(zhǎng)春瑞濱；Gemcitabineplusvinor

3、elbineinthetreatmentofadvancednon-smallcellcancerunendurablecisp1atinum-basedchemotherapyCHENqun，LIyuhong,SIqing,XIEqiang,CHENyuyan,WANGchenhui,WANGlin?DepartmentofTomour，F(xiàn)uzhouPulmonaryHospital,Fuzhou350008，China?[Abstract]ObjectiveToevaluatetheefficacyandtoxicityo

4、fgemcitabineplusvinorelbineinthetreatmentofadvancednon-smallcellcancer(NSCLC)unendurablecisp1atinum-basedchemotherapy.Methods108patientsofthestage3and4NSCLCwithECOGcountsW2point,survivaltimemorethanthreemonths,countsofWBC>4.0X10"/L,functionofliverandkidneyarenormal,

5、noinfectsymptom.allpatientstreatedpreviouslywithoutradiotherapyandchemotherapy,inthose36patientstreatedwithgemcitabineplusvinorelbine(GN)、another36pationtstreatedwithgemcitabinepluscisplatin(GP),and36patienlsvinorelbinepluscisplatin?ResultsTheoverallresponserateswer

6、e44.4%inthegroupGP,41.7%inthegroupNPand36.1%inthegroupGN.NostatisticaldifferenceintheRRbetweenthreemethodsofchemotherapy,(x2=0.421,P=1.731,P>0.05).AlsothatintheTimeToProgress,LifeQuality,SymptomaticRespondandtheYearSurvivalRate?ToxicityofI11~1Vdegreehaematologywerei

7、ndistinguishablybetweenthegroupGNandtheanothertwogroups(P>0.05).Toxicityofnon-haematologyofthegroupGNweremarked(P<0.01=.ConclusionThegroupGNhadthehigherefficacy,thattoxicitywaslower.ItiswelltolerancefortheadvancedNSCLC.ThegroupGNmaybefitforthespecialadvancedNSCLCune

8、ndurablecisplatinum-basedchemotherapy?[keywords]Non-smallcellcancer;Chemotherapy;Gemcitabine;Vinorelbine正文吉西他濱（GEM,G）和長(zhǎng)春瑞賓（NVB,N）等第三代抗癌?藥物